The global biosimilar monoclonal antibody market revenue was around US$ 10.6 billion in 2023 and is estimated to reach US$ 64.7 billion by 2032, growing at a compound annual growth rate (CAGR) of 22.2% during the forecast period from 2024 to 2032.

Biosimilar monoclonal antibodies (mAbs) are a type of biopharmaceutical products that are identical in terms of operation, structure, and therapeutic effect to existing connection or originator monoclonal antibodies. Monoclonal antibodies are big protein molecules created to target certain molecules or antigens in the body with high accuracy, making them useful in treating a broad range of diseases, including autoimmune disorders, cancer, and inflammatory conditions.

Factors Influencing Market Growth

- The major factors propelling the growth of the biosimilar monoclonal antibody market are the rise in the prevalence of breast cancer, awareness about early diagnosis, and the adoption of novel treatment alternatives for breast cancer.

- The broad range of applications lets biosimilar manufacturers target different disease domains, contributing to the comprehensive growth of the biosimilar monoclonal antibody market.

- Biotech companies, particularly smaller ones, are anticipated to struggle to confirm investment as risk aversion becomes dominant in uncertain economic times. This, in turn, could slow the development of promising biosimilar prospects, affecting the growth of the market.

- Collaborations can promote knowledge sharing, access to advanced technologies, and rapid development timelines. These partnerships can play a vital role in accelerating the commercialization and development of biosimilar mAbs, thereby propelling the market forecast.

Impact of COVID-19

The impact of the COVID-19 pandemic had a dual influence on the biosimilar monoclonal antibody market. Supply chain troubles and regulatory uncertainties posed challenges to the market, concerning distribution and manufacturing. Simultaneously, COVID-19 stressed the significance of cost-effective biologic therapies, prompting augmented interest in biosimilars. Healthcare systems, tested by the COVID-19 pandemic's financial fallout, desired affordable treatment choices, propelling the adoption of biosimilars.

Regional Analysis

In 2023, North America dominated the global biosimilar monoclonal antibody market in terms of revenue and is anticipated to stay dominant during the forecast period. This growth is due to factors like the rise in several regulatory licenses, and strong healthcare infrastructure facilitating the efficient distribution and adoption of biosimilars. In addition, strong physician acceptance, and favorable reimbursement policies, patient access, developed research & development and manufacturing capabilities, and bold efforts to increase education and awareness about biosimilar mAbs further drive the market growth.

Also, Asia-Pacific is expected to notice notable growth during the forecast period. This is attributed to the rise in demand for cost-effective treatments because of the presence of an aging and large population exposed to chronic diseases, the growth in several people suffering from chronic diseases, the increasing investments in biopharmaceutical manufacturing and research abilities, and the alliances between international and local pharmaceutical companies, which all collectively promote a favorable environment for the adoption and development of biosimilar mAbs in this region.

Leading Companies

The leading prominent companies profiled in the global biosimilar monoclonal antibody market are: -

- Novartis AG
- Pfizer Inc.
- Amgen Inc.
- Coherus BioSciences, Inc.
- Teva Pharmaceutical Industries Limited
- Shanghai Henlius Biotech, Inc.
- BIOCAD
- Biogen
- Biocon and Celltrion Healthcare Co., Ltd.
- Other prominent key players

Segmentation Outline

The global biosimilar monoclonal antibody market segmentation focuses on Type, Indication, End User, and Region.

Segmentation based on Type

- Adalimumab
- Bevacizumab
- Infliximab
- Rituximab
- Trastuzumab
- Others

Segmentation based on Indication

- Oncology
- Autoimmune diseases
- Others

Segmentation based on End User

- Hospitals
- Cancer treatment centers
- Others

Segmentation based on Region

- North America
- The U.S.
- Canada
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Netherlands
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Singapore
- Rest Of Asia-Pacific
- LAMEA
- Latin America
- Middle East
- Africa